

R&D Pipeline

(As of May 10, 2024)



Code Generic name (Product name)	Indication	Preclinical	Clinical Trial	Application	Approval	Mechanism
JR-141 pabinafusp alfa (IZCARGO® for I.V. infusion 10mg)	MPS type II (Hunter)		Global Ph3			BBB-penetrating iduronate-2-sulfatase (rDNA origin)
JR-171 lepunafusp alfa	MPS type I (Hurler etc.)		Global Ph1/2			BBB-penetrating α-L-iduronidase (rDNA origin)
JR-142	Pediatric growth hormone deficiency		Japan Ph2			Long-acting human growth hormone (rDNA origin)
JR-031HIE Human (allogeneic) bone marrow-derived mesenchymal stem cells (TEMCELL® HS Inj.)	Neonatal Hypoxic Ischemic Encephalopathy		Japan Ph1/2			Human (Allogeneic) Bone Marrow Derived Mesenchymal Stem Cells
JR-441	MPS type III A (Sanfilippo A)		Global Ph1/2			BBB-penetrating heparan N-sulfatase (rDNA origin)
JR-446	MPS type III B (Sanfilippo B)					BBB-penetrating α-N-acetylglucosam (rDNA origin)
JR-471	fucosidosis					BBB-penetrating α-L-fucosidase (rDNA origin)
JR-479	GM2 gangliosidosis (Tay-Sachs, Sandhoff)					BBB-penetrating β-Hexosaminidase A (rDNA origin)
JR-162	Pompe disease					BBB-penetrating acid α-glucosidase (rDNA origin)
JR-443	MPS type VII (Sly)					BBB-penetrating β-glucuronidase (rDNA origin)